Results 191 to 200 of about 25,224 (259)

Biomarker‐Based Diagnosis and Care Pathways for Alzheimer's Disease in the Era of Disease‐Modifying Treatments: A Consensus Statement by Belgian Experts

European Journal of Neurology, Volume 33, Issue 8, August 2026.
ABSTRACT Background The recent approval of disease‐modifying therapies (DMTs) for early Alzheimer's disease (AD) marks a major shift in clinical practice. Biomarker confirmation of amyloid pathology is now required alongside clinical assessment, and blood‐based tests are improving accessibility.
Tim Van Langenhove, Sara Van Mossevelde, Marijke Miatton, Jan De Lepeleire, Rose Bruffaerts, Jean Christophe Bier, Kurt Segers, Jurn Verschraegen, Mirko Petrovic, Manfredi Ventura, Haroun Jedidi, Ingo Beyer, Eric Mormont, Rik Vandenberghe, Aline Delva, Christian Gilles, Donatienne Van Weehaeghe, Gaëtane Picard, Peter De Deyn, Mélanie Strauss, Evert Thiery, Eric Salmon, Gert Cypers, Joris Vlaemynck, Katrin Gillis, Jan Versijpt, Maria Bjerke, Anne Sieben, Bernard Hanseeuw, Sebastiaan Engelborghs, Olivier Deryck, on behalf of the BeDeCo members   +31 more
wiley   +1 more source

Heterogeneity of white matter hyperintensities in Alzheimer's disease captured by multimodal neuroimaging. [PDF]

Sci Rep
Garnier-Crussard A, Landeau B, Mezenge F, Gonneaud J, Roquet D, Cotton F, Chetelat G.   +6 more
europepmc   +1 more source

Gait Impairment and Alzheimer's Disease Pathology: A Narrative Review on Mechanistic Links

Geriatrics &Gerontology International, Volume 26, Issue 8, August 2026.
Gait impairment and AD‐related pathology may be linked through shared risks, preclinical AD changes, feedback effects of persistent gait dysfunction, and life‐course susceptibility, underscoring the importance of maintaining brain–body health across the lifespan. ABSTRACT In older adults, gait has emerged as an important indicator of overall health and
Ryota Sakurai, Manuel Montero‐Odasso
wiley   +1 more source

Therapeutic Time Window of Disease‐Modifying Therapy for Early Alzheimer's Disease in Japanese Individuals: Analysis Based on J‐ADNI Study

Geriatrics &Gerontology International, Volume 26, Issue 8, August 2026.
In Japanese individuals with early Alzheimer's disease, baseline MMSE and CDR‐GS predicted the remaining therapeutic eligibility window for anti‐amyloid disease‐modifying therapies. These simple clinical measures may support patient triage, waiting‐list management, and timely treatment initiation under resource constraints.
Saki Nakashima, Kenichiro Sato, Yoshiki Niimi, Ryoko Ihara, Kazushi Suzuki, Atsushi Iwata, Wataru Satake, Takeshi Iwatsubo, Japanese Alzheimer's Disease Neuroimaging Initiative   +8 more
wiley   +1 more source

A study on the correlation between APOE gene polymorphism, white matter hyperintensities, and neuropsychiatric symptom phenotypes in Alzheimer's disease. [PDF]

Front Psychiatry
Fan W, Wang Z, Wan S, Liu M, Han Y, Liu X, Xu L, Wang X, Zhang D, Cai Q.   +9 more
europepmc   +1 more source